HeyJaredJACC Global
Explore cardiovascular science from a global perspective with JACC Global. This podcast highlights original research, regional innovations, and urgent challenges in heart health across diverse healthcare settings worldwide.
- Indexed episodes, last 90 days
- 11
- Latest publication
- Sep 15, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 7, 2026
Latest episodes
Is “Normal” Hemoglobin Really Normal in Heart Failure? | JACC Baran (opens the original)
Read excerpt
Hosts Mitsuaki Sawano, MD, and Satoshi Shoji, MD, welcome Misato Chimura, MD, PhD (University of Glasgow) to discuss her ESC SimPub paper in JACC, “Low-normal hemoglobin concentrations and clinical outcomes in heart failure.” Using individual participant-level data from 11 randomized trials including 42,213 patients across the full LVEF spectrum, the study examined the continuous relationship between hemoglobin and clinical outcomes. Risk was lowest around 14 g/dL in women and 15 g/dL in men, wh
BRIDGING the Lipid Management Gap After ACS: ESC Late-Breaker | JACC Baran (opens the original)
Read excerpt
Hosts Mitsuaki Sawano, MD, and Shun Kohsaka, MD, welcome Kazuma Ohyama, MD, PhD (Tohoku University) to discuss the BRIDGE trial, Protocol-Based Implementation of Early Intensive Lipid Management After Acute Coronary Syndrome. In this 10-center cluster-randomized trial, hospitals were assigned to either protocol-based or standard lipid management after emergency PCI for ACS. Rather than simply reminding clinicians to intensify therapy, the intervention specified what treatment to initiate, when t
ESC 2026 Special: JACC SimPub Papers You Should Know | JACC Baran (opens the original)
Read excerpt
Hosts Mitsuaki Sawano, MD, Takeshi Kitai, MD, PhD, Kentaro Ejiri, MD, PhD, and Satoshi Shoji, MD, PhD, highlight three JACC papers presented at ESC 2026 and simultaneously published with the meeting. Dr. Kitai discusses new HELIOS-B insights on whether the benefits of vutrisiran in transthyretin amyloidosis with cardiomyopathy are maintained among patients already receiving tafamidis. Dr. Ejiri reviews a nationwide Swedish study of nearly 500,000 heart failure hospitalizations examining how cold
The Lancet: OPTIMA-AF, Is 1 Month Enough After PCI? | JACC Baran (opens the original)
Read excerpt
Hosts Mitsuaki Sawano, MD, Shun Kohsaka, MD, Nobuhiro Ikemura, MD, and Satoshi Shoji, MD, welcome Yohei Sotomi, MD, PhD (The University of Osaka), and Ken Kozuma, MD, PhD (Teikyo University) for a special episode made possible through the JACC–Lancet partnership to discuss the OPTIMA-AF trial, published in The Lancet. In this investigator-initiated, multicenter randomized trial of 1,079 patients with atrial fibrillation undergoing PCI, 1 month of DOAC plus a P2Y12 inhibitor followed by DOAC mono
HFpEF: Why Earlier May Be Better | JACC Baran (opens the original)
Read excerpt
Hosts Mitsuaki Sawano, MD, Nobuhiro Ikemura, MD, and Satoshi Shoji, MD welcome Shunichi Doi, MD (St. Marianna University School of Medicine) to discuss his JACC: Heart Failure study, Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF: Insights From REDUCE LAP-HF II. In this prespecified subanalysis of the REDUCE LAP-HF II trial, 522 patients with HFpEF or HFmrEF were categorized by time since heart failure diagnosis (3 years). Longer disease dur
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.